Whether Daprodustat is an HDAC inhibitor and analysis of its pharmacological mechanism

Daprodustat is not a HDAC inhibitor. It is an oral small molecule drug, mainly used as a regulator of erythropoietin (Erythropoietin, EPO) synthesis and a HIF- prolyl hydroxylase (HIF-PH) inhibitor. The drug inhibits the activity of prolyl hydroxylase and stabilizes intracellular hypoxia-inducible factor (HIF), thereby promoting the production of endogenous EPO, ultimately increasing red blood cell production and improving anemia symptoms. It is especially suitable for patients with anemia related to chronic kidney disease.

Specifically, the pharmacological mechanism of daprostat is to inhibit the hydroxylation of HIF-α subunit by prolyl hydroxylase (PHD). Under normal oxygen concentration conditions, PHD will promote HIF-α to be rapidly degraded. Under hypoxic conditions, PHD activity decreases, and HIF-α can stabilize and activate erythropoiesis-related genes. Daprostat simulates a hypoxic environment, blocks the hydroxylation modification of PHD, and prolongs the half-life of HIF-α, thereby promoting hemoglobin synthesis.

In comparison, HDAC inhibitors (histone deacetylase inhibitors) are a class of drugs that affect gene expression by regulating histone acetylation status. They are mainly used for the treatment of certain tumors and immune diseases, such as vorinostat (Vorinostat). The mechanism of action of HDAC inhibitors is completely different from the HIF pathway regulation of daporostat, and there is no overlap between the two in terms of targets and therapeutic areas.

In summary, daporostat is a HIF-PH inhibitor that promotes erythropoiesis by stabilizing hypoxia-inducible factors and is used to treat anemia, rather than a HDAC inhibitor. Understanding the differences in mechanisms between the two can help with precise medication use and avoid confusion.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat